In summary, this study defines MS4A6A as a macrophage-anchored regulator enriched in Ribo-TAMs, which shapes an immunosuppressive, perivascular niche in GBM by activating the NF-κB–COX-2–PGE2 signaling axis. The gene discussed is PTGS2; the disease is glioblastoma.